Iron parameters in 84 MDS patients enrolled in a deferasirox (Exjade®, ICL670) multicenter trial.

被引：0
|
作者：
List, Alan F.
Esposito, Jason
Decker, Jodie
Baer, Maria R.
Powell, Bayard
Steensma, David
Raza, Azra
Terebelo, Howard
Maciejewski, Jaroslaw
Goldberg, Stuart L.
Paley, Carole
机构：
[1] H Lee Moffitt Canc Ctr, Tampa, FL USA
[2] Nov Pharma Corp, E Hanover, NJ USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Massachusetts, Worcester, MA 01605 USA
[7] Providence Canc Ctr, Southfield, MI USA
[8] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4847
引用
收藏
页码：297B / 297B
页数：1
相关论文
共 50 条
  • [1] Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670)
    Gattermann, N.
    Schmid, M.
    Vassilieff, D.
    Rose, C.
    Porta, M. G. Dell
    Finelli, C.
    Taylor, K.
    Seymour, J. F.
    Lee, J. W.
    Jakobs, P.
    Domokos, G.
    Hadler, D.
    LEUKEMIA RESEARCH, 2007, 31 : S109 - S110
  • [2] Clinical evaluation of deferasirox (Exjade®, ICL670)
    Porter, John
    SEMINARS IN HEMATOLOGY, 2007, 44 (02) : S16 - S20
  • [3] Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis
    Porter, J
    Borgna-Pignatti, C
    Baccarani, M
    Saviano, A
    Abish, S
    Malizia, R
    Nick, H
    Opitz, H
    Rabault, B
    Gathmann, I
    Marks, P
    BLOOD, 2005, 106 (11) : 755A - 756A
  • [4] Deferasirox (Exjade®, ICL670) preclinical overview
    Nick, Hanspeter
    SEMINARS IN HEMATOLOGY, 2007, 44 (02) : S12 - S15
  • [5] Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East:: The ESCALATOR trial.
    Taher, A
    El-Beshlawy, A
    Al Jefri, A
    El Alfy, M
    Al Zir, K
    Daar, S
    Al-Damanhouri, G
    Hadler, D
    Krahn, U
    BLOOD, 2005, 106 (11) : 40B - 41B
  • [6] Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS)
    List, Alan F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    BLOOD, 2007, 110 (11) : 440A - 440A
  • [7] Deferasirox (Exjade®, ICL670):: A journey into labile iron centers of living cardiomyocytes.
    Cabantchik, ZI
    Link, G
    Glickstein, H
    Ben El, R
    Hershko, C
    Konijn, AM
    Nick, H
    BLOOD, 2005, 106 (11) : 243A - 243A
  • [8] Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade®, ICL670).
    Cohen, A
    Masera, G
    Zoumbos, N
    Uysal, Z
    Boulet, D
    Watman, N
    Loggetto, S
    Opitz, H
    Gathmann, I
    Alberti, D
    BLOOD, 2005, 106 (11) : 242A - 242A
  • [9] Deferasirox (Exjade®, ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients
    Kattamis, C
    Kilinc, Y
    Fattoum, S
    Ferster, A
    Gallisai, D
    Maggio, A
    Dresse, MF
    Klingebiel, T
    Bourantas, K
    Canatan, D
    Maseruka, H
    Gathmann, I
    Ford, J
    BLOOD, 2005, 106 (11) : 756A - 756A
  • [10] Plasma LPI in β-thalassemia patients before and after treatment with deferasirox (Exjade®, ICL670).
    Daar, S
    Taher, A
    Pathare, A
    Krahn, U
    Gathmann, I
    Nick, H
    Hadler, D
    BLOOD, 2005, 106 (11) : 758A - 758A
12345